PubRank

A Cervantes

Author PubWeight™ 95.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 16.83
2 ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012 5.32
3 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010 2.54
4 Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003 2.53
5 The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2013 2.53
6 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005 2.33
7 Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 2.31
8 Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012 2.04
9 Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013 1.87
10 Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013 1.73
11 Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010 1.69
12 Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013 1.68
13 Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010 1.55
14 Health care delivery system. Effects on surgical education: the Mexican panorama. World J Surg 1994 1.41
15 Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 1.34
16 Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013 1.29
17 Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005 1.26
18 Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 1.18
19 The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011 1.10
20 Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 1989 1.09
21 Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 1.05
22 Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003 1.04
23 Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014 1.03
24 Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998 1.02
25 Structural bases of the cytolytic mechanisms of Entamoeba histolytica. J Protozool 1985 1.01
26 Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008 0.97
27 Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2009 0.96
28 HLA and Heberden's nodes in Mexican Mestizos. Clin Rheumatol 1985 0.94
29 Maternal race/ethnicity and twinning rates in the United States, 1989-1991. J Reprod Med 2001 0.94
30 Complex effects of stromal cell-derived factor-1 alpha on melanin-concentrating hormone neuron excitability. Eur J Neurosci 2005 0.94
31 Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis 2004 0.93
32 A mutation in the 5' non-high mobility group box region of the SRY gene in patients with Turner syndrome and Y mosaicism. J Clin Endocrinol Metab 2000 0.93
33 Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013 0.92
34 Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994 0.92
35 Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010 0.92
36 Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Ann Oncol 2010 0.91
37 Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 2009 0.91
38 Undergraduate training in oncology: an ESO continuing challenge for medical students. Surg Oncol 2010 0.89
39 A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996 0.88
40 HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol 2013 0.87
41 Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. Eur J Cancer 2011 0.86
42 Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol 2001 0.85
43 Stromal cell-derived factor-1alpha directly modulates voltage-dependent currents of the action potential in mammalian neuronal cells. J Neurochem 2005 0.85
44 Raltitrexed: current clinical status and future directions. Ann Oncol 2002 0.85
45 Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993 0.84
46 Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study. Clin Transl Oncol 2013 0.83
47 SRY alone can induce normal male sexual differentiation. Am J Med Genet 1995 0.83
48 Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998 0.82
49 Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. Clin Exp Metastasis 2014 0.82
50 Frequency of Y chromosomal material in Mexican patients with Ullrich-Turner syndrome. Am J Med Genet 1998 0.82
51 Clinical traits and molecular findings in 46,XX males. Clin Genet 1995 0.82
52 Prognostic implications of circumferential location of distal rectal cancer. Colorectal Dis 2010 0.81
53 Mix gonadal dysgenesis associated with ring Y chromosome mosaics in a phenotypic male. Sex Dev 2009 0.80
54 A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Cancer 1995 0.80
55 Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Ann Oncol 2012 0.80
56 Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol 1999 0.80
57 Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines. Eur J Oncol Nurs 2012 0.80
58 Oncology for medical students: a European School of Oncology contribution to undergraduate cancer education. Cancer Treat Rev 2007 0.79
59 FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol 2009 0.79
60 Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations. Hum Mutat 2003 0.79
61 Effects of steroidal antifertility agents after two to six years of continuous use. Int J Fertil 1967 0.79
62 Clinical, Cytogenetic, and Biochemical Analyses of a Family with a t(3;13)(q26.2;p11.2): Further Delineation of 3q Duplication Syndrome. Case Rep Genet 2013 0.78
63 Molecular analysis in true hermaphrodites with different karyotypes and similar phenotypes. Am J Med Genet 1996 0.78
64 HLA-DR4 and rheumatoid arthritis in Mexican mestizos. Arthritis Rheum 1984 0.78
65 Trisomy 3q25.1-qter and monosomy 8p23.1-pter in a patient: cytogenetic and molecular analysis with delineation of the phenotype. Am J Med Genet A 2005 0.77
66 Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines. Ann Oncol 2011 0.77
67 Etoposide (E) + epirubicin (E) + cisplatin (P) combination chemotherapy (EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Therapy (T.T.D.). Ann Oncol 1992 0.77
68 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol 2005 0.77
69 GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol 2013 0.76
70 UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (Williston Park) 1999 0.76
71 Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'. Ann Oncol 2013 0.75
72 Biomarkers in colorectal cancer: the future is getting closer. Clin Transl Oncol 2010 0.75
73 A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol 2004 0.75
74 The autopsy in modern oncology: a quality assessment of clinical care. Ann Oncol 1991 0.75
75 [The family planning program of the Secretaría de Salubridad y Asitencia in the border states]. Salud Publica Mex 1981 0.75
76 Painful Baker's cysts. Differential diagnosis by scintillation scanning with technetium Tc 99m. JAMA 1969 0.75
77 [Extrinsic compression of the right atrium due to a mediastinal germ-cell tumor]. Rev Esp Cardiol 1991 0.75
78 What interventions are useful in reducing the rate of preterm delivery in twins? Clin Obstet Gynecol 1998 0.75
79 Fertility control with norgestrel and ethynil estradiol. Report on continuing studies. J Reprod Med 1972 0.75
80 [Clinical studies on Ovostat--a combined oral contraceptive with a low dose of lynestrenol]. Geburtshilfe Frauenheilkd 1974 0.75
81 [Acceptability of medroxyprogesterone acetate among medical and paramedical personnel in family planning]. Ginecol Obstet Mex 1982 0.75
82 Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins. Am J Obstet Gynecol 1975 0.75
83 [Characteristics of persons accepting the Program of Family Planning of the Secretary of Health and Assistance during 1978]. Salud Publica Mex 1981 0.75
84 Optimizing the APC residue washing process to minimize the release of chloride and heavy metals. Waste Manag 2005 0.75
85 Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). Clin Transl Oncol 2006 0.75
86 Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1996 0.75
87 Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol 2003 0.75
88 Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol 1998 0.75
89 [Hormonal contraceptives, peripheral venous insufficiency and the use of a phlebodynamic agent]. Ginecol Obstet Mex 1976 0.75
90 [Involvement of the private physician to the family planning programs: pilot study]. Ginecol Obstet Mex 1979 0.75
91 [Effects of steroid agents as contraceptives after 2 to 6 years of continuous use]. Ginecol Obstet Mex 1967 0.75
92 [Contraception and fertility. Analysis of 1090 pregnancies]. Ginecol Obstet Mex 1978 0.75
93 [Genetic disorders of the adult age]. Gac Med Mex 1996 0.75
94 The evolving role of oxaliplatin in the management of colorectal cancer. Colorectal Dis 2003 0.75
95 ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines. Ann Oncol 2012 0.75
96 Pregnancy and progeny after hormonal contraceptives--genetic studies. J Reprod Med 1971 0.75
97 The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). J Infus Chemother 1996 0.75
98 [Mechanism of action of intrauterine devices]. Ginecol Obstet Mex 1979 0.75
99 Clinical study of a continuous daily micro-dose progestogen contraceptive--d-norgestrel. Contraception 1972 0.75
100 [New method for the early diagnosis of pregnancy]. Ginecol Obstet Mex 1980 0.75
101 Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma. Oncology 1994 0.75
102 [The teaching of family planning in the medical schools of Mexico]. Ginecol Obstet Mex 1979 0.75
103 "H" reflex as a measure of subclinical uremic polyneuropathy in children with chronic renal failure. Adv Perit Dial 1997 0.75
104 Appearance of color matchings under various chromatic adaptation conditions. Optom Vis Sci 1989 0.75
105 [Estrogen and progesterone receptors in cancer of the breast]. Med Clin (Barc) 1987 0.75
106 [Characteristics of women participating in the family planning program of the Direccion General de Atencion Medica Materna Infantil y Planificacion Familiar de la SSA]. Salud Publica Mex 1979 0.75
107 Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer. Ann Oncol 2004 0.75
108 [Injectable contraceptives. 10 years' clinical experience]. Ginecol Obstet Mex 1973 0.75
109 The ESMO guideline strategy: an identity statement and reflections on improvement. Ann Oncol 2015 0.75
110 [Treatment of locally advanced cancer of the breast]. Med Clin (Barc) 1987 0.75
111 Absence of capillary microangiopathy in oral contraceptive users with glucose intolerance. Obstet Gynecol 1978 0.75
112 Lead over-exposure in a foundry due to a neighbouring industrial process. Occup Med (Lond) 1994 0.75
113 [Secretion of growth hormone in men and women during the reproductive age, in aged men and menopausal women with or without estrogens or progesterone]. Ginecol Obstet Mex 1979 0.75
114 Integration of new or experimental treatment options and new approaches to clinical trials. Ann Oncol 2005 0.75
115 [Regulation of fertility in lactation]. Gac Med Mex 1978 0.75